S
Sprint Bioscience AB
STO:SPRINT
Sprint Bioscience AB
STO:SPRINT
Price:
1.91
SEK
0.79%
Market Cap:
kr201.5m
Relative Value
The Relative Value of one SPRINT stock under the Base Case scenario is 2.65 SEK. Compared to the current market price of 1.91 SEK, Sprint Bioscience AB is Undervalued by 28%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SPRINT
Relative Value
Base Case
2.65
SEK
Undervaluation 28%
S
Multiples Across Competitors
SPRINT Competitors Multiples
Sprint Bioscience AB Competitors
Sprint Bioscience AB Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
S
|
Sprint Bioscience AB
STO:SPRINT
|
201.5m SEK | 1.2 | 2.2 | 0.8 | 0.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
404.2B USD | 6.6 | 96.7 | 15.8 | 22 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.5B USD | 5.6 | 26.5 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182.8B USD | 6.3 | 21.8 | 13.5 | 16.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.7B USD | 10.5 | 31.8 | 24 | 25.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.7B AUD | 3.2 | 34.9 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.2B EUR | 11.1 | 35.7 | 38.8 | 39.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
